SCHEMBL659333

SCHEMBL659333

CC(=O)c1cc(Cl)cc(Cl)c1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C4 P17516 1/20 0.67
AKR1C3 P42330 1/20 0.67
AKR1C2 P52895 1/20 0.67
AKR1C1 Q04828 1/20 0.67
ALDH1A1 P00352 3/20 0.54
CYP3A4 P08684 2/20 0.54
TSHR P16473 2/20 0.54
RECQL P46063 2/20 0.54
HSD17B10 Q99714 2/20 0.54
MAPK1 P28482 3/20 0.53
TBXAS1 P24557 2/20 0.53
MAPK14 Q16539 2/20 0.53
PTGS1 P23219 1/20 0.53
PTGS2 P35354 1/20 0.53
STK39 Q9UEW8 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
ERN1 O75460 1/20 0.45
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29613154 1.00 AKR1C4 (0.67) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL11332675 0.89 AKR1C4 (0.50) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL12316474 0.83 KDM4E (0.46) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL4127393 0.83 AKR1C2 (0.45) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL11712068 0.81 AKR1C2 (0.46) AKR1C4AKR1C3AKR1C2AKR1C1MAPK1
SCHEMBL6175638 0.81 AKR1C2 (0.64) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL29495446 0.81 BCL2L1 (0.50) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL10469179 0.81 BCL2L1 (0.50) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL184603 0.80 AKR1C2 (1.00) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1
SCHEMBL4891035 0.80 AKR1C4 (0.69) AKR1C4AKR1C3AKR1C2AKR1C1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12269909-B2 Polymer composition and a method of preparing a polymer resin AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2025-04-08 US claimed
CN-114751870-B 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof 贵州医科大学 2023-10-20 CN claimed
EP-4165134-A1 FLUOROSILICONE POLYMERS, COMPOSITIONS, AND USES THEREOF ForSight Vision6, Inc. (US) 2023-04-19 EP claimed
CN-114751870-A 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and derivative thereof, and synthesis method and application thereof 贵州医科大学 2022-07-15 CN claimed
US-20220041781-A1 A Polymer Composition and a Method of Preparing a Polymer Resin AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-02-10 US claimed
WO-2021257518-A1 FLUOROSILICONE POLYMERS, COMPOSITIONS, AND USES THEREOF FORSIGHT VISION6, INC. (US) 2021-12-23 WO claimed
WO-2020130941-A1 A POLYMER COMPOSITION AND A METHOD OF PREPARING A POLYMER RESIN AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-06-25 WO claimed
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction BIODERM RESEARCH (US) 2008-10-16 US claimed
US-20060269494-A1 New Ubiquitin-Proteasome Regulating Compounds and Their Application in Cosmetic and Pharmaceutical Formulations GUPTA SHYAM K 2006-11-30 US claimed
US-20060110415-A1 Topical Delivery System for Cosmetic and Pharmaceutical Agents BIODERM RESEARCH (US) 2006-05-25 US claimed
US-20060074108-A1 Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition BIODERM RESEARCH (US) 2006-04-06 US claimed
US-20050271608-A1 Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives GUPTA SHYAM K 2005-12-08 US claimed
EP-1066269-B1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA NV (BE) 2005-05-11 EP claimed
US-20020115668-A1 Trisubstituted 1,3,5-triazine derivatives DAEYAERT FREDERIK FRANS DESIRE (BE) 2002-08-22 US claimed
EP-1066269-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 2001-01-10 EP claimed
US-6150360-A ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE JANSSEN PHARMACEUTICA N.V. (BE) 2000-11-21 US claimed
WO-1999050256-A1 TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS JANSSEN PHARMACEUTICA N.V. (BE) 1999-10-07 WO claimed
US-12594147-B2 Curable composition for use in a high temperature lithography-based photopolymerization process and method of producing crosslinked polymers therefrom ALIGN TECHNOLOGY, INC. (US) 2026-04-07 US disclosed
US-4002423-A Benzofuran derivatives process for their preparation and their use as optical brighteners HOECHST AKTIENGESELLSCHAFT (DT) 1977-01-11 US disclosed
US-3933472-A Substituted alkylaryl ketones and methods of use as herbicides BUCKMAN LABORATORIES, INC. (US) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115668-A1 Trisubstituted 1,3,5-triazine derivatives XDH, CCR5, CXCR1 AKR1C4 260/4885AKR1C3 156/4885AKR1C2 359/4885
US-20080254130-A1 Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction PSMB1, PLOD3, CUTA AKR1C4 2651/4885AKR1C3 2434/4885AKR1C2 2513/4885
US-12594147-B2 Curable composition for use in a high temperature lithography-based photopolymerization process and method of producing crosslinked polymers therefrom MACF1, DYNC1LI2, DYNLL2 AKR1C4 4311/4885AKR1C3 4060/4885AKR1C2 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.